Growth of orphan drug market puts the World Orphan Drug Congress USA in the spotlight

Differently from the uncertainty of the economic growth across developed countries, the pharmaceutical industry is optimistic about the increasing revenue from orphan drug development. In a recent report conducted by BCC Research, the orphan drug market in 2012 was evaluated in $82 billion and is expected to grow at an average rate of 5.4% in the next five years, to …

Reimbursement: economics of orphan drugs and the impact of rarity on the estimation of cost effectiveness ration

Increasing pressures on health care budgets have led to a growing interest in the use of economic evaluation in reimbursement decisions for drugs and other health technologies. This has a great impact in the access of orphan drugs by rare disease patients. In this scenario, insurance companies are starting to assess the value for money by comparing the incremental costs …

eBook: Top 10 Orphan Drug Pipelines in Europe

Who has the most robust and promising pipeline of orphan medicinal products in Europe? This is the question we asked ourselves as we brought together the speaking faculty and constructed the programme for the 4th Annual World Orphan Drug Congress in Geneva. As the orphan drug market grows at an enviable rate, the pharmaceutical industry have shifted focus and investments …

Orphan drugs, no longer orphan?

Have orphan drugs found a home? It seems that this is the case for a lot of rare disease therapies being developed, as pharma and biotechs, along with investors, have understood that producing orphan drugs can be a potent money maker. It all started with the first orphan drug approved by the FDA from Genzyme to treat Gaucher's Disease and …

Download: Optimising Clinical Development & Speeding Patient Access to Orphan Drugs

In preparation for the 2014 World Orphan Drug Congress in Geneva, we have collated a number of interviews from some of the leading orphan drug developers. The industry-at-large are investing more and more resources into rare disease research, and numerous companies are now deploying the scientific, regulatory and strategic expertise to progressed an orphan drug to market. With over 7000 …

OrphanReach: Healthcare at Home and QED partner on orphan diseases

Healthcare at Home and QED partner on orphan diseases OrphanReach alliance will see companies provide product lifecycle services Healthcare at Home and QED Clinical Services have formed a strategic alliance under the OrphanReach banner to support the launch of products for rare and orphan diseases. Homecare and patient support company Healthcare at Home and QED Clinical Services, a clinical research …

Top 5 Presentations from Last year’s World Orphan Drug Congress Europe

As the agenda and speaking faculty takes shape for the 4th Annual World Orphan Drug Congress Europe, we wanted to take a look back at some of the leading presentations, debates and discussions that took place at last year's event. According to a new 2013 Orphan Drug Industry Report from Evaluate, the worldwide orphan drug market is set to reach …

2013 Rare & Orphan Advocacy and Research (ROAR) Awards – VOTING NOW OPEN

Voting is now open for the 2013 ROAR Awards, the Rare and Orphan Drug Industries' Awards ceremony recognising and celebrating achievements across the commercial, patient and alliance organisations in the last 12 months. With 10 hotly contested awards open for nomination, make your votes count for individuals and organisations that have shown best in class in 2012/2013. Make your nominations …

How to Navigate the Thai Orphan Drug System

Learn in depth about the orphan drug system in Thailand from the Thai Food and Drug Administration's presentation. Gain insight on what are orphan drugs in Thailand and what problems in orphan drug development should be prioritised. In addition, understand orphan drug registration as well as the funding, reimbursement, supply, and distribution of orphan drugs, and learn how to increase …

Indus Biotech Presentation

Understand about the shifting paradigms in investing in orphan drug development from Indus Biotech. Orphan drugs and its policies in the USA, EU and Asia will be discussed, along with the challenges in its development. Thus, learn about the emerging opportunities for Botanical Drugs that can aid in reducing drug development cost and time to market as well as mitigate …